TB-CHAMP Trial Reveals key risk factors for TB Infection in children under five years of age.Young children have a high risk ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Infectious Diseases, Department of Internal Medicine, Nanavati Max Super Speciality Hospital, highlights the effectiveness of ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

Iterum Therapeutics Announces Partnership for Commercialization Services U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at ...

FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

A new review has examined how bipolar disorder medications interact with the gut microbiome, revealing important links ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer FDA recommends inclusion of patients as young as 6 months - younger than ...

Treating urine infections is becoming increasingly challenging due to rising antibiotic resistance. Here's what's driving this issue and how to address it.

Development of a predictive model for risk factors of multidrug-resistant bacterial pneumonia in critically ill post-neurosurgical patients Provisionally accepted . Aixiang Hu 1 dayan ma 2 yanni lei 3 ...